McKesson stock costs EUR 853.20 with USD 111.3 billion market cap

Published on 10/12/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock is EUR 853.20 on October 12, 2026, versus EUR 836.60 at Xetra. That is plus 1.98 percent versus the Xetra close.

Key points in brief

McKesson stock was EUR 853.20 at Lang & Schwarz on October 12, 2026, 1.98 percent above the EUR 836.60 Xetra close.
NYSE data put McKesson at USD 950.88, with a market capitalization of USD 111.3 billion and a 52-week range of USD 723.68 to USD 999.00.
Leerink Partners raised its target from USD 1,030.00 to USD 1,070.00 on October 7, 2026, according to MarketBeat.
McKesson is scheduled to report second-quarter fiscal 2027 results on November 4, 2026.

Mitarbeiter sortieren unbeschriftete Pakete in einem großen Pharma-Logistiklager mit Regalen — Fotorealistisches Bild zeigt McKesson Corporation ISIN US58155Q1031 als Pharmagroßhändler in modernem Distributionslager mit vielen Mitarbeitern, Illustration mit AI erstellt.

McKesson (ISIN US58155Q1031) was trading at EUR 853.20 at Lang & Schwarz on October 12, 2026 at 4:12 p.m. CEST, or 1.98 percent above the EUR 836.60 Xetra close of October 9, 2026. The euro quotation gives German investors a clear intraday market reference while the primary listing remains in New York.

Intraday quote stays active

McKesson was last at USD 950.88 on the NYSE on October 12, 2026 at 10:23 a.m. ET. The session range in the same primary-market quotation was USD 936.77 to USD 956.24, with volume of 104,798 shares against an average of 917,881 shares.

At Lang & Schwarz, the bid was EUR 850.80 and the ask was EUR 855.60 at the quoted time. The spread places the current euro price between two closely separated executable indications rather than at an official exchange close.

Range and valuation levels

McKesson's 52-week NYSE range is USD 723.68 to USD 999.00. The USD 950.88 primary-market price is 4.82 percent below the 52-week high, calculated against the USD 999.00 upper bound.

The company carried a market capitalization of USD 111.3 billion on October 12, 2026, while the price-to-earnings ratio was 25.46. The valuation figures belong to the NYSE quotation and are separate from the euro price at Lang & Schwarz.

Analyst target and next date

According to MarketBeat on October 7, 2026, Leerink Partners raised its McKesson target from USD 1,030.00 to USD 1,070.00 and maintained an Outperform rating. The same report listed 14 Buy ratings and four Holds, alongside a consensus target of USD 973.19.

Simply Wall St lists November 4, 2026 as McKesson's next earnings date for second-quarter fiscal 2027 results. That event supplies the next scheduled checkpoint for revenue, earnings per share and guidance.

Comparison with peers

McKesson (NYSE, USD): plus 1.98 percent, P/E 25.46, market capitalization USD 111.3 billion

Cardinal Health (NYSE, USD): minus 0.18 percent, P/E 32.83, market capitalization USD 55.5 billion

Cencora (NYSE, USD): , , market capitalization USD 61.8 billion

Price remains above Xetra close

The McKesson quotation was EUR 853.20 at Lang & Schwarz on October 12, 2026 at 4:12 p.m. CEST, compared with the EUR 836.60 Xetra close of October 9, 2026. The further course of trading is shown by the continuously updated real-time quote of McKesson stock.